Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 10/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20289365 | 1.00 | ACACB (0.49) | ACACBCNR1GAAHPGDSMN1; SMN2 | |
| SCHEMBL21799081 | 1.00 | ACACB (0.49) | ACACBCNR1GAAHPGDSMN1; SMN2 | |
| SCHEMBL21799124 | 0.85 | ACACB (0.48) | ACACBCNR1GAAHPGDSMN1; SMN2 | |
| SCHEMBL20289737 | 0.85 | ACACB (0.48) | ACACBCNR1GAAHPGDSMN1; SMN2 | |
| SCHEMBL20289695 | 0.85 | ACACB (0.48) | ACACBCNR1GAAHPGDSMN1; SMN2 | |
| SCHEMBL21378363 | 0.81 | CNR1 (0.45) | ACACBCNR1 | |
| SCHEMBL19700693 | 0.81 | CNR1 (0.45) | ACACBCNR1 | |
| SCHEMBL20270226 | 0.80 | CNR1 (0.44) | ACACBCNR1POLB | |
| SCHEMBL20270225 | 0.80 | CNR1 (0.44) | ACACBCNR1POLB | |
| SCHEMBL19692717 | 0.80 | ACACB (0.48) | ACACBCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206780-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | ELI LILLY AND COMPANY | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206780-A1 | 7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AS MUTANT IDH1 AND IDH2 INHIBITORS | IDH2, IDH1, IDH3B | ACACB 996/4885CNR1 4540/4885GAA 1551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.